跳至主要内容
临床试验/NCT04255420
NCT04255420Unknown4 期

Sphenopalatine Ganglion Blocks for Headaches in the Emergency Department

Kendall Healthcare Group, Ltd.1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2020年2月21日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
入组人数
84
试验地点
1
主要终点
Percentage of Patients with Substantial Pain Reduction at 15 minutes

研究概览

简要总结

This will be a single-center, open-label clinical trial comparing sphenopalatine ganglion blocks to standard intravenous therapy for patients who come to the emergency department for a headache.

详细描述

Having outperformed other agents in head-to-head trials, intravenous (IV) dopamine antagonists, such as prochlorperazine or metoclopramide, are generally considered the 1st line treatment for headaches in the ED. However, despite the relative effectiveness of prochlorperazine, a substantial number of patients who present to the ED with a headache still have a moderate to severe headache 24 hours after discharge. Moreover, some patients may have difficult IV access, so it would be useful to employ a technique that could effectively treat headaches without the use of an IV line.

One therapy that has been suggested but not well-studied that might help treat headaches in the ED without the use of an IV line is the sphenopalatine ganglion (SPG) block via intranasal lidocaine. The sphenopalatine ganglion may play a role in the development of pain in primary headaches through the release of neuropeptides that activate or sensitize intracranial nociceptors. Several prior randomized trials have evaluated the use of intranasal lidocaine or bupivacaine vs placebo for patients with migraine headaches, and the results have been mixed.

Thus, the investigators propose a single-center, open-label, clinical trial to compare the efficacy of SPG blocks to standard IV therapy for headaches in the ED.

Adult patients who come to the ED for a suspected primary headache may be enrolled. Patients who are assigned to the standard IV therapy group will receive prochlorperazine 10 mg and diphenhydramine 50 mg.

Patients who are assigned to the SPG block group will undergo the following procedure. A cotton-tipped applicator soaked in 1% lidocaine will be placed in the nostril on the side of the headache. If the headache is bilateral, a cotton-tipped applicator will be inserted into each nostril. The cotton-tipped applicator(s) will be left in place for 15 minutes. If the patient has not had significant improvement upon removal of the cotton-tipped applicator the physician may order IV medication for the patient's headache ("rescue analgesia").

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Any patient at least 18 years old who presented to the ED with a suspected primary headache.

排除标准

  • pregnant women
  • prisoners
  • meningeal signs
  • any acute abnormality on neurologic exam
  • allergy to one of study drugs
  • on oral anticoagulant
  • already received analgesic treatment in the ED

研究组 & 干预措施

SPG Block

Experimental

Sphenopalatine ganglion block using cotton-tipped applicators soaked in 1% lidocaine will be performed.

干预措施: SPG Block (Procedure)

Standard Treatment

Active Comparator

Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg.

干预措施: Standard IV Treatment (Drug)

结局指标

主要结局

Percentage of Patients with Substantial Pain Reduction at 15 minutes

时间窗: 15 minutes

The percentage of patients whose 100 mm visual analog scale pain score reduced by at least 50% from before treatment until 15 minutes after the start of treatment.

次要结局

  • Change in Mean Pain Score at 30 minutes(30 minutes)
  • Change in Mean Pain Score at 15 minutes(15 minutes)
  • Headache 24-72 hours later(24-72 hours)
  • Hospital Length of Stay(30 minutes to 1 week)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验